October 24, 2024

Overall Survival Analysis Confirms Pembrolizumab Regimen as Standard of Care for Triple-Negative Breast Cancer

For women with early-stage triple-negative breast cancer, KEYNOTE-522 changed the treatment paradigm several years ago. Support for neoadjuvant use of the PD-1 inhibitor pembrolizumab plus chemotherap...

The ASCO Post

October 31, 2024

PEACE-3: Enzalutamide Plus Radium-223 Significantly Improves Survival in Metastatic Castration-Resistant Prostate Cancer

The ASCO Post

October 24, 2024

NO-CUT Trial: Nonoperative Management of Benefit for Many Patients With Rectal Cancer

The ASCO Post

October 24, 2024

KEYNOTE-811: Pembrolizumab Combination in First-Line Setting Improves Overall Survival in Gastric Cancer

The ASCO Post

October 24, 2024

ADRIATIC Trial: Durvalumab Consolidation Extends Survival in Limited-Stage Small Cell Lung Cancer

The ASCO Post

October 09, 2024

HIMALAYA: 5-Year Analysis Confirms Survival Benefit of STRIDE Regimen in Hepatocellular Carcinoma

The ASCO Post

Latest Headlines

January 01, 2025

Daratumumab Induction Regimen in Transplant-Ineligible Patients Newly Diagnosed with Multiple Myeloma

The ASCO Post

December 23, 2024

SEQUOIA 5-Year Follow-up: Zanubrutinib vs Bendamustine/Rituximab in Treatment-Naive CLL/SLL

The ASCO Post

December 23, 2024

FDA Grants Accelerated Approval to Encorafenib Combination for BRAF V600E–Mutant Metastatic Colorectal Cancer

The ASCO Post

December 23, 2024

Long-Term Overall Survival With Adjuvant Gemcitabine/Capecitabine vs Gemcitabine in Pancreatic Adenocarcinoma

The ASCO Post

December 23, 2024

Primary Analysis of ZUMA-2: Treatment of BTK Inhibitor–Naive Relapsed/Refractory Mantle Cell Lymphoma

The ASCO Post

December 23, 2024

Primary Analysis of ZUMA-2: Treatment of BTK Inhibitor–Naive Relapsed/Refractory Mantle Cell Lymphoma

The ASCO Post

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.

Conference Coverage

All Conference News View Conference Calendar

2024 International Myeloma Society Annual Meeting

January 01, 2025

Daratumumab Induction Regimen in Transplant-Ineligible Patients Newly Diagnosed with Multiple Myeloma

The ASCO Post

November 08, 2024

Evolving Role of MRD Status in Multiple Myeloma

The ASCO Post

2024 ASH Annual Meeting

December 23, 2024

Primary Analysis of ZUMA-2: Treatment of BTK Inhibitor–Naive Relapsed/Refractory Mantle Cell Lymphoma

The ASCO Post

December 23, 2024

Combination of Two Oral Agents May Improve Progression-Free Survival in Patients With Previously Untreated CLL

The ASCO Post

December 20, 2024

Epcoritamab Monotherapy for Pretreated Relapsed or Refractory CLL

The ASCO Post

ESMO Congress 2024

December 19, 2024

KEYNOTE-811: Pembrolizumab Combination in First-Line Setting Improves Overall Survival in Gastric Cancer

The ASCO Post

December 09, 2024

Adding Chemoradiation in Perioperative Gastric Cancer Treatment Improves Pathologic Response Rates Without Survival Benefit

The ASCO Post

December 09, 2024

I-SPY2.2: Dato-DXd Plus Durvalumab Yields High Pathologic Response Rate in Breast Cancer Subset

The ASCO Post

Clinical Guidelines

December 23, 2024

FDA Grants Accelerated Approval to Encorafenib Combination for BRAF V600E–Mutant Metastatic Colorectal Cancer

The ASCO Post

December 13, 2024

My Cancer Diagnosis and Renewed Commitment to Fight for Patients

The ASCO Post

December 09, 2024

Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?

The ASCO Post

December 09, 2024

Accelerated Approval Granted to Zanidatamab-hrii for HER2-Positive Biliary Tract Cancer

The ASCO Post

Commentary & Perspectives

July 10, 2023

Expert Point of View: Pamela L. Kunz, MD and Corrie Marijnen, MD, PhD

The ASCO Post

January 25, 2023

Communicating Prognosis: A Core Competency of Patient-Centered Oncology Care

The ASCO Post

June 09, 2023

Rethinking Prior Authorization

The ASCO Post

October 25, 2023

Gender Equity in Academic Hematology: Where There’s a ‘WiL,’ There’s a Way

The ASCO Post

FDA & Government News

December 19, 2024

Mesenchymal Cell Therapy Approved for Steroid-Refractory Acute GVHD

The ASCO Post

December 16, 2024

Cosibelimab-ipdl Approved by FDA for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

The ASCO Post

December 09, 2024

FDA Approves Novel Companion Diagnostic Assay

The ASCO Post

December 05, 2024

FDA Grants Approval to New Bispecific Antibody for NSCLC and Pancreatic Adenocarcinoma

The ASCO Post

Business Management

April 01, 2023

Change is Constant

Inside Dental Hygiene

February 08, 2023

Machine Learning and the Power to Outsmart Cancer

Cedars-Sinai Pulse

June 10, 2024

How the Museum of Medicine and Biomedical Discovery Aims to Bring Scientific Achievements of the Past, Present, and Future to Life

The ASCO Post

March 01, 2023

Exceeding Patient Expectations With Bioceramic Cements and More

Inside Dentistry

Trending Now

Trending Now

Find topic & conditions by first letter

Compendium

Inside Dental Hygiene

Inside Dental Technology

Inside Dentistry

Special Issues

The ASCO Post

JADPRO

JNCCN

JNCCN 360

Corneal Physician

Glaucoma Physician

New Retinal Physician

Ophthalmology Management

Ophthalmic Professional

Presbyopia Physician

Retinal Physician

Contact Lens Spectrum

Eyecare Business

Optometric Management

Presbyopia Physician

KEYNOTE-811: Pembrolizumab Combination in First-Line Setting Improves Overall Survival in Gastric Cancer

ADRIATIC Trial: Durvalumab Consolidation Extends Survival in Limited-Stage Small Cell Lung Cancer

HIMALAYA: 5-Year Analysis Confirms Survival Benefit of STRIDE Regimen in Hepatocellular Carcinoma

Latest Headlines

Daily News

Recommendations

Featured Videos

Conference Coverage

2024 International Myeloma Society Annual Meeting

2024 ASH Annual Meeting

ESMO Congress 2024

Clinical Guidelines

Commentary & Perspectives

FDA & Government News

Business Management